MX340564B - Isoformas de neurregulina solubles activas modificadas post-traduccionalmente. - Google Patents

Isoformas de neurregulina solubles activas modificadas post-traduccionalmente.

Info

Publication number
MX340564B
MX340564B MX2010005205A MX2010005205A MX340564B MX 340564 B MX340564 B MX 340564B MX 2010005205 A MX2010005205 A MX 2010005205A MX 2010005205 A MX2010005205 A MX 2010005205A MX 340564 B MX340564 B MX 340564B
Authority
MX
Mexico
Prior art keywords
translationally modified
active soluble
soluble post
neuregulin isoforms
isoforms
Prior art date
Application number
MX2010005205A
Other languages
English (en)
Other versions
MX2010005205A (es
Inventor
Schrattenholz André
Original Assignee
Mind-Nrg Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mind-Nrg Sa filed Critical Mind-Nrg Sa
Publication of MX2010005205A publication Critical patent/MX2010005205A/es
Publication of MX340564B publication Critical patent/MX340564B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF] (urogastrone)

Abstract

La presente invención se refiere a isoformas solubles neurregulina-1 que representan modificaciones pos-traduccionales de neurregulina-1 como medicación en trastornos neurológicos relacionados con la cognición, en particular esquizofrenia y enfermedades de Alzheimer y enfermedad de Parkinson.
MX2010005205A 2007-11-16 2008-11-17 Isoformas de neurregulina solubles activas modificadas post-traduccionalmente. MX340564B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98857607P 2007-11-16 2007-11-16
PCT/EP2008/009715 WO2009062750A2 (en) 2007-11-16 2008-11-17 Active soluble post-translationally modified neuregulin isoforms

Publications (2)

Publication Number Publication Date
MX2010005205A MX2010005205A (es) 2010-10-26
MX340564B true MX340564B (es) 2016-07-14

Family

ID=40545995

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005205A MX340564B (es) 2007-11-16 2008-11-17 Isoformas de neurregulina solubles activas modificadas post-traduccionalmente.

Country Status (13)

Country Link
US (9) US20100256066A1 (es)
EP (1) EP2219662B1 (es)
JP (2) JP5650537B2 (es)
CN (2) CN101903036A (es)
AU (1) AU2008323169B2 (es)
BR (2) BR122020025248B1 (es)
CA (1) CA2705328C (es)
DK (1) DK2219662T3 (es)
ES (1) ES2414058T3 (es)
MX (1) MX340564B (es)
PT (1) PT2219662E (es)
RU (1) RU2491955C2 (es)
WO (1) WO2009062750A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399452A1 (en) * 2000-02-11 2001-08-16 Proteosys Ag. Use of neuregulin-.beta. as an indicator and/or target
US20100256066A1 (en) 2007-11-16 2010-10-07 Proteosys Ag Active soluble post-translationally modified neuregulin isoforms
MX2014001766A (es) * 2011-08-17 2014-05-01 Genentech Inc Anticuerpos de neuregulina y sus usos.
CN102327613A (zh) * 2011-09-02 2012-01-25 浙江大学 ErbB受体激动剂在制备治疗癫痫病的药物中的应用
CN103083645A (zh) * 2011-10-27 2013-05-08 中国科学院上海生命科学研究院 神经调节素1及其受体作为制备或筛选抗癫痫药物靶点的用途
JP6342627B2 (ja) * 2013-08-02 2018-06-13 国立大学法人 東京大学 筋萎縮性側索硬化症の新規病因遺伝子
CN108732355B (zh) * 2017-04-25 2021-06-25 首都医科大学附属北京安定医院 一种测定bace1酶切nrg1活性的检测方法及其试剂盒

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US6087323A (en) 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
US5770567A (en) * 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
US6750196B1 (en) 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
WO1999018976A1 (en) 1997-10-14 1999-04-22 Cambridge Neuroscience, Inc. Therapeutic methods comprising use of a neuregulin
NL1014232C2 (nl) 2000-01-31 2001-08-01 Dsm Nv Zout van een melaminecondensatieproduct en een fosfor bevattend zuur.
CA2399452A1 (en) 2000-02-11 2001-08-16 Proteosys Ag. Use of neuregulin-.beta. as an indicator and/or target
CA2400595A1 (en) * 2000-02-28 2001-09-07 Decode Genetics Ehf Human schizophrenia gene
US7824923B2 (en) * 2001-08-06 2010-11-02 Proteosys Ag Neuregulin-β isoforms associated with neuronal processes
AU2002349583B2 (en) 2001-11-28 2007-11-22 Anges Mg, Inc. Genetic remedies for neurodegenerative diseases
US20040191818A1 (en) * 2003-02-26 2004-09-30 O'toole Margot Mary Compositions and methods for diagnosing and treating autoimmune diseases
US8466144B2 (en) 2004-07-16 2013-06-18 Proteosys Ag Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
EP1981525B1 (en) * 2005-12-30 2015-01-21 Zensun (Shanghai) Science and Technology Limited Extended release of neuregulin for improved cardiac function
WO2007113366A1 (es) * 2006-04-05 2007-10-11 Consejo Superior De Investigaciones Científicas Uso de compuestos inductores del desarrollo axonal de neuronas, composiciones terapéuticas que los contienen y sus aplicaciones
US20100256066A1 (en) 2007-11-16 2010-10-07 Proteosys Ag Active soluble post-translationally modified neuregulin isoforms

Also Published As

Publication number Publication date
DK2219662T3 (da) 2013-06-24
BRPI0820538A2 (pt) 2015-06-16
ES2414058T3 (es) 2013-07-18
CN105561299A (zh) 2016-05-11
US10350269B2 (en) 2019-07-16
CN101903036A (zh) 2010-12-01
US20140323408A1 (en) 2014-10-30
US10813978B2 (en) 2020-10-27
US20140243270A1 (en) 2014-08-28
CA2705328C (en) 2018-01-02
PT2219662E (pt) 2013-06-28
EP2219662A2 (en) 2010-08-25
EP2219662B1 (en) 2013-04-24
JP5913426B2 (ja) 2016-04-27
WO2009062750A2 (en) 2009-05-22
US20210128687A1 (en) 2021-05-06
AU2008323169A1 (en) 2009-05-22
US20190307848A1 (en) 2019-10-10
JP5650537B2 (ja) 2015-01-07
CA2705328A1 (en) 2009-05-22
RU2010124429A (ru) 2011-12-27
RU2491955C2 (ru) 2013-09-10
BRPI0820538B1 (pt) 2021-08-17
JP2011503134A (ja) 2011-01-27
US20170035849A1 (en) 2017-02-09
JP2014193879A (ja) 2014-10-09
US20100256066A1 (en) 2010-10-07
BR122020025248B1 (pt) 2022-05-03
US20210077579A1 (en) 2021-03-18
US20140243269A1 (en) 2014-08-28
AU2008323169B2 (en) 2013-08-29
WO2009062750A3 (en) 2009-09-24
US20150239948A1 (en) 2015-08-27
MX2010005205A (es) 2010-10-26

Similar Documents

Publication Publication Date Title
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
MX340564B (es) Isoformas de neurregulina solubles activas modificadas post-traduccionalmente.
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
MY161415A (en) A homeopathic formulation
WO2007022506A3 (en) Methods and compositions for treating neurological disease
WO2007092329A3 (en) Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
IN2012DN02763A (es)
WO2007002516A3 (en) Improved dosage forms for movement disorder treatment
MX2020012868A (es) Metodos y composiciones para trastornos del sue?o y otros trastornos.
WO2006058868A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
WO2007142755A3 (en) Purine analogs
WO2006048242A3 (en) Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
MX2007012237A (es) Amilina y agonistas de amilina para tratar enfermedades y trastornos siquiatricos.
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
MX2012004551A (es) Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal.
EA200901621A1 (ru) Индукция толерогенного фенотипа у зрелых дендритных клеток
WO2010009478A3 (en) Compositions and methods for treating disorders associated with overweight animals
MX2009010407A (es) Derivados fluorados de deferiprona.
MX2012013735A (es) Isoformas de neuregulina, polipeptidos de neuregulina y usos de los mismos.
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
MX340807B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
MX2007006754A (es) Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos.
EP2069377A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES AND SKIN FUNCTIONAL DISORDERS

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: MIND-NRG SA

FG Grant or registration